department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Brinsupri · pharmadog

pharmadog
drugs
Brinsupri

drug

patient view →

brensocatib

Marketedupdated 2mo ago

by $INSM INSMED Inc

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Brinsupri

generic

brensocatib

indication

Bronchiectasis

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 49m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 12, 2030

~4.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (28)

Feb 21, 2040formulationUS 12059424
Feb 21, 2040formulationUS 12059424
Mar 1, 2039formulationUS 12201638
Mar 1, 2039formulationUS 12201638
Mar 12, 2035compositionUS 9522894
Mar 12, 2035compositionUS 9522894
Jan 21, 2035compositionUS 10287258
Jan 21, 2035compositionUS 10287258
Jan 21, 2035compositionUS 10669245
Jan 21, 2035compositionUS 10669245
Jan 21, 2035formulationUS 11655221
Jan 21, 2035formulationUS 11655221
Jan 21, 2035compositionUS 11655222
Jan 21, 2035compositionUS 11655222
Jan 21, 2035compositionUS 11655223
Jan 21, 2035compositionUS 11655223
Jan 21, 2035formulationUS 11655224
Jan 21, 2035formulationUS 11655224
Jan 21, 2035formulationUS 11673871
Jan 21, 2035formulationUS 11673871
Jan 21, 2035formulationUS 11773069
Jan 21, 2035formulationUS 11773069
Jan 21, 2035compositionUS 11814359
Jan 21, 2035compositionUS 11814359
Jan 21, 2035compositionUS 12054465
Jan 21, 2035compositionUS 12054465
Jan 21, 2035method-of-use (U-4257)US 9815805
Jan 21, 2035method-of-use (U-4257)US 9815805

FDA exclusivities (2)

Aug 12, 2030NCENew Chemical Entity (5y)4.1y
Aug 12, 2030NCENew Chemical Entity (5y)4.1y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying brensocatib

phase2A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosiscompletedn=29
phase2A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)active not recruitingn=214
phase3A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasiscompletedn=1,767
phase2A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)completedn=288
—An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasisapproved for marketing
phase1A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy Participantscompletedn=24
phase1A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participantscompletedn=20
phase1A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participantscompletedn=22

more trials →